Aug 13, 2012
(Reuters) – Acorda Therapeutics Inc said on Monday that a low-dose version of its multiple sclerosis drug Ampyra did not work in a clinical study, a potentially positive result that will hold generic competition at bay until 2027.A post-marketing study of Ampyra failed to show an improvement in patients’ walking speed when 5 mg of the drug was given twice a day. Had the 5 mg version worked, generic rivals could have entered the market in 2017 or 2018.
Continue reading
(Reuters) – Acorda Therapeutics Inc said on Monday that a low-dose version of its multiple sclerosis drug Ampyra did not work in a clinical study, a potentially positive result that will hold generic competition at bay until 2027.A post-marketing study of Ampyra failed to show an improvement in patients’ walking speed when 5 mg of the drug was given twice a day. Had the 5 mg version worked, generic rivals could have entered the market in 2017 or 2018.
Continue reading
..
We appreciate commenting on our stories.
Please note that all comments are moderated.
LIKE this Blog by clicking the LIKE button – top left
REMAIN up to date with MS News, Information and Education
Visit: www.msviewsandnews.org to sign-up
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
